1. Home
  2. NPWR vs CRDF Comparison

NPWR vs CRDF Comparison

Compare NPWR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NET Power Inc.

NPWR

NET Power Inc.

HOLD

Current Price

$2.14

Market Cap

193.9M

Sector

Energy

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.60

Market Cap

187.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPWR
CRDF
Founded
2010
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.9M
187.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NPWR
CRDF
Price
$2.14
$1.60
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$3.50
$10.83
AVG Volume (30 Days)
822.2K
1.8M
Earning Date
03-09-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$501,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
42.86
N/A
52 Week Low
$1.48
$1.48
52 Week High
$8.87
$4.99

Technical Indicators

Market Signals
Indicator
NPWR
CRDF
Relative Strength Index (RSI) 31.74 27.95
Support Level $1.96 $1.48
Resistance Level $2.43 $1.76
Average True Range (ATR) 0.14 0.16
MACD -0.04 -0.12
Stochastic Oscillator 12.12 2.55

Price Performance

Historical Comparison
NPWR
CRDF

About NPWR NET Power Inc.

NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: